Alembic share news, announcements and annual reports
NSE: ALEMBICLTDBSE: 506235RealtySmall Cap
Alembic Limited · Formerly Alembic Chemical Works Co. · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1934 on BSE, Sep 1999 on NSE
Last close ₹89.31up ₹1.72 (1.96%)BSE ₹89.45
Share price at the NSE close on 29 Oct 2026. Previous close ₹87.59.
29 Oct: open ₹87.00, high ₹89.49, low ₹86.86
52-week range of traded prices to 29 Oct 2026
₹70.46Low, 30 Mar 2026₹117.72High, 3 Sep 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,293 Cr1,101st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 7.15
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.69%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,69,68150.2% delivered
Alembic board meetings
116 filed, newest first. Page 3 of 3.
Apr 2010
26 Apr · Board meeting
To consider and approve, inter-alia, the Audited Financial Results for the year ended on March 31, 2010 (April 01, 2009 to March 31, 2010). In the said Board Meeting, the Board of Directors will also consider recommendation of dividend, if any, on equity shares for the year 2009-10.
Jan 2010
13 Jan · Board meeting
To consider and approve, interalia, Un-audited Financial Results for the quarter ended on December 31, 2009 (October 1, 2009 to December 31, 2009).
Oct 2009
7 Oct · Board meeting
To consider and approve, inter-alia, Un-audited Financial Results for the quarter ended on September 30, 2009 (July 01, 2009 to September 30, 2009).
Jul 2009
16 Jul · Board meeting
To consider and approve, inter-alia, Un-audited Financial Results for the quarter ended on June 30, 2009 (April 01, 2009 to June 30, 2009).
Apr 2009
29 Apr · Board meeting
To consider and approve, inter-alia, the Audited Financial Results for the year ended on March 31, 2009 (April 01, 2008 to March 31, 2009). In the said Board Meeting, the Board of Directors will also consider dividend payment, if any, on equity shares for the year 2008-09.
Jan 2009
19 Jan · Board meeting
To consider and approve, inter-alia, the Un-audited Financial Results for the Third quarter ended on December 31, 2008 (October 01, 2008 to December 31, 2008).
Nov 2008
7 Nov · Board meeting
Inter-alia, to consider, buy back of equity shares of the Company.
Oct 2008
10 Oct · Board meeting
To consider and approve, inter-alia, the Un-audited Financial Results for the Second quarter ended on September 30, 2008 (July 01, 2008 to September 30, 2008).
Jul 2008
14 Jul · Board meeting
Meeting on 28 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
17 Apr · Board meeting
To consider and approve, inter-alia, the Audited Financial Results for the year ended on March 31, 2008 (April 01, 2007 to March 31, 2008).
Jan 2008
16 Jan · Board meeting
Meeting on 24 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
8 Oct · Board meeting
Meeting on 17 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
10 Jul · Board meeting
Meeting on 18 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
10 May · Board meeting
To consider inter alia, Audited Financial Results for the year ended on March 31, 2007 and to recommend dividend, if any, for the year 2006 - 07.
Feb 2007
1 Feb · Board meeting
At the meeting of the Board of Directors of the Company held on 31-January-2007 considered and approved the acquisition of Domestic Non-Oncology Formulation Business comprising the brands, trademarks, copyrights , designs, development, manufacture, formulations, trading, marketing, trademarks and distribution of the Non-Oncology products of M/s Dabur Pharma Ltd. New Delhi on an going concern basis together with the assets (including all rights, privileges, and benefits of use and exploitation of Brands Trade marks, Copyrights, Design and full power and authority in respect of the Technology, Know-how, License, Franchises, Business & Marketing Information, Current Assets and Continuing Employee etc) and assume all Agreed Liabilities forming part of the said Division at the Closing Date as a going concern / running business. The consideration for acquisition shall be Rs. 159 Crores plus actual net working capital on the closing date. This acquisition will be subject to such statutory and Regulatory approvals as may be required to be taken by the seller and the purchaser.
Jan 2007
3 Jan · Board meeting
To consider inter-alia, Unaudited Financial Results for the Third quarter ended on December 31,2006. (October, 2006 to December, 2006).